The Onco'Zine Brief Peter Hofland

In this –this episode of the Onco’Zine Brief, Peter Hofland talks with Dr. Matthias Bucerius.

Dr. Bucerius is Vice President and General Manager at MilliporeSigma. He is responsible for Contract Development and Manufacturing Organsation (CDMO) business of the company, leading a fully integrated global team with Manufacturing Operations, Commercial, Marketing & Strategy, Technology & Innovation organizations.

The company is helping its clients in developing and manufacturing a variety of products, including antibody-drug conjugates.

Antibody-drug conjugates or ADCs are targeted therapies that have opened new ways in targeting diseases like cancer and hematological malignancies.

What is unique about ADCs is that they leverage the specific targetability benefits offered by antibodies and combine that with the high potency of small-molecule drugs. This combination makes these agents uniquely targetable therapies. And unlike traditional chemotherapy, these ADCs target tumors by delivering the attached payload to destroy cancer cells while sparing the healthy or normal cells, thereby potentially reducing negative side effects for patients.

In the 100th episode of the Onco’Zine Brief, Peter Hofland, Ph.D. talks with Stephen Spellman, Vice President of Research and Senior Scientific Director of the Center for International Blood and Marrow Transplant Research at the National Marrow Donor Program/Be the Match.

In the program today Hofland and Spellman talk about bone-marrow transplants.

The likelihood of finding a fully matched unrelated donor for a patient who needs a bone marrow transplantvaries greatly depending on a patient’s ethnic background, and that ethnically diverse patients have – historically – been at a disadvantage. However, new research shows that when donor registry models are expanded to include mismatched unrelated donors, finding access for patients may greatly improve.[1]

Based on this understanding, Spellman believes that mismatched unrelated donors hold the key to erasing the gap in donor availability and deliver allogeneic hematopoietic cell transplantation (HCT) to all patient populations.

For more information about the Center for International Blood and Marrow Transplant Research, please visit the organization’s website.

About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to download our Media Kit, visit Patreon at or contact the sales team.

For more information about cancer and cancer treatments, visit our online journal Onco'Zine.

To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. The Onco’Zine Brief is made possible, in part, by Java Original Coffee – the home of artisan roasted coffee.

Reference
[1] Spellman S. Is finding a Donor for All in Need of Allogeneic HCT Possible? New Modeling Says Yes – Onco’Zine on September 5, 2022. [Link to article]

In this edition of The Onco'Zine Brief, Peter Hofland, Ph.D, talks with Susanna F. Greer, Ph.D. the Chief Scientific Officer of the V Foundation. In her role, Dr. Greer is a visionary ambassador of the V Foundation, who works with the foundation’s Scientific Advisory Committee to steer funding to the most promising research opportunities.

An accomplished strategist, she develops and articulates priorities to enhance the V Foundation’s research portfolio, gifts, grants, and sponsorships that advance the V Foundation’s distinctive brand of cutting-edge and disruptive research.

The V Foundation was founded in 1993 by ESPN and the late Jim Valvano, legendary NC State University basketball coach and ESPN commentator. The mission of the V Foundation is to funds game-changing research and all-star scientists to accelerate Victory Over Cancer® and save lives. Today the V Foundation funds research for all cancer types, at leading cancer centers and research facilities nationwide. The organization awards 100% of direct donations to cancer research and programs. The Foundation’s endowment covers administrative expenses.


About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to download our Media Kit, visit Patreon at or contact the sales team.

For more information about cancer and cancer treatments, visit our online journal Onco'Zine.

To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

The Onco’Zine Brief is made possible, in part, by Java Original Coffee – the home of artisan roasted coffee.

Despite availability of endocrine therapies for advanced or metastatic breast cancer, there remains a critical unmet need for more effective and convenient treatment options that improve both the patient experience and health outcomes.

In today’s episode of The Onco’Zine Brief, Peter Hofland, Ph.D. talks with Sean P. Bohen, MD, Ph.D., the president and Chief Executive Officer of Olema Therapeutics.

Olema Terapeutics is developing new treatment options designed to improve outcomes for women with metastatic breast cancer. The company’s lead investigational drug is OP-1250.
This drug is a is a novel agent with combined activity as both an advanced complete estrogen receptor antagonist, and a selective estrogen receptor degrader. This approach is expected to drive deeper, more durable responses than currently available therapies.

OP-1250 is currently in development as a treatment for estrogen receptor-positive, HER2-negative metastatic breast cancer (ER+/HER2- MBC), in both monotherapy and combination settings.

About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to download our Media Kit, visit Patreon at or contact the sales team.

For more information about cancer and cancer treatments, visit our online journal Onco'Zine.

To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

The Onco’Zine Brief is made possible, in part, by Java Original Coffee – the home of artisan roasted coffee.

Clinical trials
- Phase 1b Combo w/ Ribociclib and Alpelisib | NCT05508906
- A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients - NCT05266105
-A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer - NCT04505826

The annual congress of the European Society for Medical oncology or ESMO, is one of the most influential oncology meetings for clinicians, researchers, patient advocates, and healthcare industry representatives from all over the world. This year the annual Congress was held September 9 - 13, 2022 in the Paris Expo Porte de Versailles in Paris, France.

In this episode of the Onco’Zine Brief, Peter Hofland, Ph.D., talks with:

- Eric Vivier DVM, Ph.D, senior vice president and scientific officer of Innate Pharma about anti-cancer drugs designed to harness the power of Natural Killer (NK-) Cells. During the ESMO Congress, the company presented a number of studies discussing the safety and efficacy of lacutamab in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2 and the design of multispecific antibodies (ANKET for antigen-specific activation of NK cells).

- Daniel Teper, PharmD, MBA, co-founder, chairperson and Chief Executive Officer of Cytovia Therapeutics, a company developing Precision NK Therapeutics which may revolutionize cancer treatment. During the annual ESMO Congress, the company presented new preclinical data for its GPC3 Flex-NK™ cell engager antibody in combination with natural killer cells.

- Neil H. Bander, MD, Director of Urological Oncology Research at Weill Cornell Medicine and Co-founder of Convergent Therapeutics about prostate cancer. The company is developing a therapeutic platform that is capable of targeting validated and novel cancer antigens, including the first antibodies to specifically target prostate-specific membrane antigen (PSMA).

About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to download our Media Kit, visit Patreon at or contact the sales team.

For more information about cancer and cancer treatments, visit our online journal Onco'Zine.

To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

The Onco’Zine Brief is made possible, in part, by Java Original Coffee – the home of artisan roasted coffee.

Clinical trials
Study of Lacutamab in Peripheral T-cell Lymphoma - NCT04984837Safety and Efficacy of Lacutamab in Patients With Relapse Peripheral T-cell Lymphoma That Express KIR3DL2 - NCT05321147IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK) - NCT03902184

Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. And while the disease can occur at any age, it tends to occur more often in older people.

According to the American Cancer Society, United States, doctors diagnose between 12,000 and 14,000 patients with glioblastoma in the U.S. each year. There is currently no cure for glioblastoma. The median length of survival after a diagnosis is 15-
18 months, while the disease’s five-year survival rate is around 10%.

And while all glioblastomas recur, initial treatments may keep the tumor controlled
for months or even years.

To improve the current standard of care, ongoing research and development is required.
Earlier this year, researchers at Modifi Biosciences published a critical study in thejournal
Science, validating a new oncology platform based on new classes of molecules
that exploit tumor-associated DNA repair defects through direct cancer cell DNA modification.

This approach redefines the rules on how to selectively kill cancer cells via direct DNA
modification

The technology bypasses conventional approaches that indirectly target proteins in cancer cells and demonstrates robust anti-tumor activity in glioma, one of the deadliest forms of brain cancer, while sparing normal tissue.

In the publication in Science, a new class of molecules were found to be very selective against cancer cells that lack expression of a key DNA repair protein.

And approximately half of all glioblastomas and up to 80% of gliomas lack this particular protein. Furthermore. emerging research indicates that this deficiency is seen in many
other tumor types, suggesting broad applicability for this strategy in treating cancer.

Based on this research, scientists at Modifi Bio are creating a new class of molecules, based on research conducted at Yale.

In this episode of The Onco’Zine Brief, Peter Hofland, Ph.D. talks with Ranjit S. Bindra, MD, Ph.D., a physician-scientist at Yale School of Medicine and the co-founder of Modify Bio.


Reference
[1] Lin K, Gueble SE, Sundaram RK, Huseman ED, Bindra RS, Herzon SB. Mechanism-based design of agents that selectively target drug-resistant glioma. Science. 2022 Jul 29;377(6605):502-511. doi: 10.1126/science.abn7570. Epub 2022 Jul 28. PMID: 35901163.

About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit Onco'Zine to download our Media Kit or visit Patreon to become a Sustaining Member of the show and support the program.

For more information about cancer and cancer treatments, visit our online journal Onco'Zine.

To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.